We've announced our newest product!|
The solution will allow labs to automate their clinical interpretation of variants based on ACMG guidelines. Our team has put together a blog series to discuss the product in more detail:
Part I By Andreas Scherer, Ph.D. | President & CEO
"The clinical interpretation of variants is time-consuming and requires attention to details. Clinicians are being asked to thoroughly review any variants that could potentially cause disease. There are guidelines for the interpretation of variants relating to hereditary risk, germline diagnostics, and molecular oncology panels�" Read More �
Part II By Andreas Scherer, Ph.D.
"So, what is all that buzz about this new product? Why do people care so much and how does it help a clinical lab? We had extensive dialogues with our customers over the last few years leading up to this product launch. The key value of VSClinical is in the following�" Read More �
Part III By Gabe Rudy | VP of Product & Engineering
"I want to cover the motivation for VSClinical and how we curated and presented the 33 criteria from the ACMG Guidelines into an intuitive workflow with various bioinformatic evidence and�" Read More �
By Gabe Rudy | VP of Product & Engineering
"We're going to go in more detail how VSClinical works, what algorithms and annotation sources power the recommendations and how the ACMG criteria are organized into useful categories. VSClinical is built to make the process of evaluating�" Read More �
By Nathan Fortier | Senior Product Engineer
"Interpretation of variants in accordance with the ACMG guidelines requires that variants near canonical splice boundaries be evaluated for their potential to disrupt gene splicing. The five most common tools for splice site detection are NNSplice, MaxEntScan, GeneSplicer, HumanSplicingFinder, and SpliceSiteFinder-like�" Read More �
We'll be adding several more posts to this series, so stay tuned on our blog to learn more about VSClinical!